

BIOCAD, SPH to build drug substance manufacturing facility in China

14 September 2018 | News

These Russian-Chinese joint ventures will be established with the main purpose of development, manufacturing, authorization, and marketing of at least six BIOCAD products.



This year at the Eastern Economic Forum in Vladivostok, BIOCAD and Shanghai Pharmaceuticals Holding entered into a Memorandum of Understanding (MoU) to create two joint ventures for production, clinical development, registration, and marketing of several high-cost medicines based on monoclonal antibodies in the People's Republic of China.

The MoU was signed by Dmitry Morozov, BIOCAD's founder and CEO, and Jun Zhou, Board Chairman at Shanghai Pharmaceuticals Holding Co.Ltd. The ceremony was attended by Denis Manturov, Minister of Industry and Trade of the Russian Federation.

These Russian-Chinese joint ventures will be established with the main purpose of development, manufacturing, authorization, and marketing of at least six BIOCAD products used in advanced therapy of cancer and autoimmune diseases (chronic lymphatic leukemia, colorectal cancer, lung cancer, breast cancer, psoriasis, ankylosing spondylitis, etc.).